Novartis seeks approval for ofatumumab to treat multiple sclerosis
Novartis announced that both the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted the company’s Supplemental Biologics License Application (sBLA)…
Read More...
Read More...
